Trial Profile
Effect of complete fasting and two hours after meal on the pharmacokinetics of Erlotinib in NSCLC patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 07 Jan 2013 New trial record